Login to Your Account



Vernalis Inks Specialty Pharma Deal with Tris, Raises $103.8M

By Nuala Moran
Staff Writer

Wednesday, February 15, 2012

LONDON – Vernalis plc has taken the decisive step in casting off its biotech roots, announcing a £65.9 million (US$103.8 million) fundraising that will enable it to enter the U.S. prescription drug market and also catapults the company's market capitalization from £20 million to £100 million.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription